Abstract:Background: Non-small cell lung cancer (NSCLC) accounts for 85 % of all lung cancers, the leading cause of cancer-related deaths worldwide. Despite recent advancements in NSCLC treatment, such as targeted therapy and immunotherapy, a large proportion of NSCLC patients develop drug resistance. Thus, development of new effective treatments for NSCLC is urgently needed. Traditional Chinese medicine may provide sources for developing new anti-cancer drugs. Although Scutellaria baicalensis (SB) has been proven to have anti-cancer effects, its action mechanism on NSCLC is not yet fully understood. Here we used network pharmacology to investigate the potential mechanism of SB treating NSCLC. Methods: We identified the active constituents of SB from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and predicted their potential targets using the SwissTargetPrediction database. Next, therapeutic targets for NSCLC were screened using five databases: GeneCards, DisGeNET, DrugBank, Online Mendelian Inheritance in Man (OMIM), and Therapeutic Target Database (TTD). A protein-protein interaction (PPI) network of the common targets between SB and NSCLC was constructed using STRING were visualized using Cytoscape. We also performed enrichment analysis of these targets to identify gene ontology (GO) and KEGG pathways associated with them. Finally, we conducted molecular docking analysis using Autodock Vina and PyMOL to investigate the interactions between active SB components and NSCLC targets. Furthermore, we performed in vitro experimental validations of the findings by bioinformatics analysis. Results: We identified 35 active compounds of SB and their 463 potential targets, and 1,073 NSCLC-associated targets. A total of 140 targets overlapped between the SB and NSCLC targets. PPI network analysis and drug-ingredient-target network analysis identified SRC, HSP90AA1, STAT3, AKT1, and MAPK3 as the core target proteins, and baicalein, 5,7,2,5-tetrahydroxy-8,6-dimethoxyflavone, skullcapflavone II, tenaxin I, and rivularin as critical active compounds of SB. GO and pathway enrichment analysis uncovered pathways significantly associated with the common targets between SB and NSCLC, including PI3K-Akt signaling, VEGF, and EGFR tyrosine kinase inhibitor resistance. Molecular docking revealed a stable binding between the main active components and core targets. In vitro experiments showed that baicalein suppressed A549 cell proliferation in a concentration-dependent manner, induced apoptosis, and caused cell cycle arrest in the S phase. Moreover, baicalein inhibited A549 cell migration and activation of the PI3K/Akt pathway. Conclusions: SB has a potential to treat NSCLC through multiple targets and pathways. This study afforded potential targets for further experimental research to explore the mechanism of SB in the treatment of NSCLC.

Phytochemical library screening reveals betulinic acid as a novel Skp2‐SCF E3 ligase inhibitor in non–small cell lung cancer

Combination Treatment With Inhibitors of ERK and Autophagy Enhances Antitumor Activity of Betulinic Acid in Non–small-Cell Lung Cancer In Vivo and In Vitro

[Betulinic acid inhibits non-small cell lung cancer by repolarizing tumor-associated macrophages via mTOR signaling pathway]

Exploring Targets and Related Mechanisms of Scutellaria Baicalensis for Treating Non-Small Cell Lung Cancer Based on Network Pharmacology

<i>Phellinus baumii</i> Polyphenol: A Potential Therapeutic Candidate against Lung Cancer Cells

Skp2 Inhibitor AAA-237 Exerts Anti-Tumor Effect on NSCLC by Inducing Mitochondria-Dependent Apoptosis and Senescence

Preclinical Pharmacodynamic Evaluation of Drug Candidate Sklb-178 in the Treatment of Non-Small Cell Lung Cancer

Discovery of flavonoid-containing compound Lupalbigenin as anti-NSCLC cancer agents via suppression of EGFR and ERK1/2 pathway

Discovery, structural optimization, and anti-tumor bioactivity evaluations of betulinic acid derivatives as a new type of RORγ antagonists

Baicalein inhibits non‐small‐cell lung cancer invasion and metastasis by reducing ezrin tension in inflammation microenvironment

Baicalein Inhibits Orthotopic Human Non-Small Cell Lung Cancer Xenografts Via Src/Id1 Pathway

A Novel Systems Pharmacology Method to Investigate Molecular Mechanisms of Scutellaria Barbata D. Don for Non-small Cell Lung Cancer.

Acetyl-11-Keto-β-Boswellic Acid Exerts the Anti-Cancer Effects Via Cell Cycle Arrest, Apoptosis Induction and Autophagy Suppression in Non-Small Cell Lung Cancer Cells

SKLB316, a Novel Small-Molecule Inhibitor of Cell-Cycle Progression, Induces G2/M Phase Arrest and Apoptosis in Vitro and Inhibits Tumor Growth in Vivo.

Baicalein Enhances the Antitumor Efficacy of Docetaxel on Nonsmall Cell Lung Cancer in a Β‐catenin‐dependent Manner

Betulinic acid inhibits stemness and EMT of pancreatic cancer cells via activation of AMPK signaling

Elucidating the mechanism of action of Isobavachalcone induced autophagy and apoptosis in non-small cell lung cancer by network pharmacology and experimental validation methods

SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.

Betulinic acid impairs metastasis and reduces immunosuppressive cells in breast cancer models

Baicalein mediates anticancer effect on cholangiocarcinoma through co-targeting the AKT/NF-κB and STAT3 signaling pathway

The most recent progress of baicalein in its anti-neoplastic effects and mechanisms